Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis

医学 产科 随机对照试验 妊娠期 相对风险 荟萃分析 早产 怀孕 置信区间 妇科 儿科 内科学 遗传学 生物
作者
Rupsa C. Boelig,Mariavittoria Locci,Gabriele Saccone,Elisabetta Gragnano,Vincenzo Berghella
出处
期刊:American Journal Of Obstetrics & Gynecology Mfm [Elsevier BV]
卷期号:4 (5): 100658-100658 被引量:13
标识
DOI:10.1016/j.ajogmf.2022.100658
摘要

Randomized trials have found benefits of both vaginal progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of recurrent preterm birth. A previous meta-analysis directly comparing the two was limited by low-quality evidence, and national and international society guidelines remain conflicting regarding progestin formulation recommended for prevention of recurrent preterm birth. The aim of this updated systematic review with meta-analysis was to evaluate the efficacy of vaginal progesterone compared with 17-alpha-hydroxyprogesterone caproate in the prevention of spontaneous preterm birth in patients with singleton gestations and previous spontaneous preterm birth.Searches were performed in MEDLINE, Ovid, Scopus, ClinicalTrials.gov, the International Prospective Register of Systematic Reviews (PROSPERO), SciELO, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) with the use of a combination of keywords and text words related to "preterm birth," "preterm delivery," "singleton," "cervical length," "progesterone," "progestogens," "vaginal," "17-alpha-hydroxy-progesterone caproate," and "intramuscular" from inception of each database to September 2021. No restrictions for language or geographic location were applied.We included all randomized controlled trials of asymptomatic singleton gestations with previous spontaneous preterm birth that were randomized to prophylactic treatment with either vaginal progesterone (ie, intervention group) or intramuscular 17-alpha-hydroxyprogesterone caproate (ie, comparison group). Post hoc sensitivity analysis was performed for studies with low risk of bias and studies with protocol registration.The primary outcome was preterm birth <34 weeks' gestation. The summary measures were reported as relative risks with 95% confidence intervals.Seven randomized controlled trials including 1910 patients were included in the meta-analysis. Patients who received vaginal progesterone had a significantly lower rate of preterm birth at <34 weeks (14.7% vs 19.9%; relative risk, 0.74; 95% confidence interval, 0.57-0.96), preterm birth at <37 weeks (36.0% vs 46.6%; relative risk, 0.76; 95% confidence interval, 0.69-0.85), and preterm birth at <32 weeks of gestation (7.9% vs 13.6%; relative risk, 0.58; 95% confidence interval, 0.39-0.86), compared with women who received intramuscular 17-alpha-hydroxyprogesterone caproate. There were no significant differences in the rate of preterm birth at <28 weeks' gestation. Adverse drug reactions were significantly lower in the vaginal progesterone group than in the 17-alpha-hydroxyprogesterone caproate group (15.6% vs 22.2%; relative risk, 0.71; 95% confidence interval, 0.54-0.92). Perinatal mortality was lower in the vaginal progesterone group than in the 17-alpha-hydroxyprogesterone caproate group (2.2% vs 4.4%; relative risk, 0.51; 95% confidence interval, 0.25-1.01). In sensitivity analysis including trials rated with at least 4 Cochrane tools as of "low risk of bias," 4 trials were included (N=575), and there was no longer a significant difference in preterm birth at <34 weeks' gestation between vaginal progesterone and 17-alpha-hydroxyprogesterone caproate (12.2% vs 13.9%; relative risk, 0.87; 95% confidence interval, 0.57-1.32).Overall, vaginal progesterone was superior to 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth at <34 weeks' gestation in singleton pregnancies with previous spontaneous preterm birth. Although sensitivity analysis of high-fidelity studies showed the same trend, findings were no longer statistically significant.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ikouyo完成签到 ,获得积分10
4秒前
语凌完成签到 ,获得积分10
9秒前
飘逸的语海完成签到 ,获得积分10
11秒前
13秒前
13秒前
HelloBOB完成签到 ,获得积分10
14秒前
青旭流觞完成签到,获得积分10
15秒前
pp完成签到 ,获得积分10
21秒前
xiaohansan完成签到 ,获得积分10
23秒前
雪流星完成签到 ,获得积分10
25秒前
qiqi完成签到 ,获得积分10
27秒前
drkyy完成签到,获得积分10
30秒前
yy完成签到,获得积分10
31秒前
seujyc完成签到 ,获得积分10
33秒前
锂电说完成签到 ,获得积分10
33秒前
庾傀斗发布了新的文献求助10
34秒前
55秒前
FIGGIEKIO发布了新的文献求助10
56秒前
hhh2018687完成签到,获得积分10
1分钟前
songrui643完成签到 ,获得积分10
1分钟前
TongKY完成签到 ,获得积分10
1分钟前
zxcvbnmgx完成签到 ,获得积分10
1分钟前
远之完成签到 ,获得积分10
1分钟前
白昼の月完成签到 ,获得积分0
1分钟前
wangdafei完成签到 ,获得积分10
1分钟前
devilito完成签到,获得积分10
1分钟前
12305014077完成签到 ,获得积分10
1分钟前
沙莎完成签到 ,获得积分10
1分钟前
Achuia完成签到,获得积分10
1分钟前
bae完成签到 ,获得积分10
1分钟前
Achuia发布了新的文献求助50
1分钟前
wgm完成签到,获得积分10
1分钟前
tiantian完成签到 ,获得积分10
1分钟前
迅速的念芹完成签到 ,获得积分10
1分钟前
淘宝完成签到,获得积分10
1分钟前
开心一夏完成签到 ,获得积分10
1分钟前
ccchill完成签到 ,获得积分10
1分钟前
Crackpot完成签到 ,获得积分10
1分钟前
蔡龙杰完成签到,获得积分10
1分钟前
arniu2008的应助被科研通管家采纳,获得80
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195296
求助须知:如何正确求助?哪些是违规求助? 9581000
关于积分的说明 21873194
捐赠科研通 7795394
什么是DOI,文献DOI怎么找? 3437988
关于科研通互助平台的介绍 2561346
邀请新用户注册赠送积分活动 2484742